Today’s announcement by Futura Medical that no further efficacy studies are likely to be required for European approval of its topical pain relief products is very encouraging as it could shorten the time to market for the products, both of which (TPR100/diclofenac and TIB200/ibuprofen) have demonstrated excellent efficacy in a controlled clinical trial. We note that the market in Europe for OTC topical pain relief products has been estimated at over $750m. We retain a positive stance on Futura ....
